DYAI
NASDAQDyadic International Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks39-33%
2026-04-192026-10-11
Mix1790d
- SEC Filings9(53%)
- Other3(18%)
- Earnings2(12%)
- Insider1(6%)
- Offering1(6%)
- Market1(6%)
Latest news
25 items- SECDyadic International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form EFFECT filed by Dyadic International Inc.EFFECT - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form 424B3 filed by Dyadic International Inc.424B3 - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form S-1 filed by Dyadic International Inc.S-1 - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- NEWSiAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026RALEIGH, NC / ACCESS Newswire / September 8, 2026 / iAccess Alpha today announced that it will host its Virtual Best Ideas Fall Investment Conference on September 15-16, 2026, bringing together small and microcap public companies and investors for two days of company presentations and 1x1 meetings. The conference will begin on Tuesday, September 15, 2026, with a series of live-streamed company presentations. The second day, Wednesday, September 16, 2026, will be dedicated to 1x1 meetings between presenting companies and pre-qualified investors.How to AttendInvestors and industry professionals may register to view presentations and request 1x1 meetings by visiting the official event website:
- SECDyadic International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form 424B5 filed by Dyadic International Inc.424B5 - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private PlacementJUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) (the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants to the same investor. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.9 million. The offering price per share of Common Stock is $0.795 and per Wa
- SECSEC Form 10-Q filed by Dyadic International Inc.10-Q - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECDyadic International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business AreasJUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion. "Our strong second-quarter performance underscores Dyadic’s ongoing transformation into a commercial-stage biotechnology leader, "said Joe Hazelton, President and COO. "We are d
- PRDyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development AgreementJUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins. The agreement further expands Dyadic's growing food and nutrition pipeline while reinforcing the Company's strategy of developing recurring revenue opportunities throu
- PRDyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended Jun 30, 2026 and host a corporate update conference call on Wednesday, August 12, 2026. Conference Call InformationDate: Wednesday, August 12, 2026Time: 5:00 p.m. Eastern Time
- PRDyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 DaysJUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately 15 days of receiving the plasmids, it developed stable pools of C1 cell lines and manufactured and initially purified two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens. In response to the active Bundibugyo ebolavirus outbreak, both C1-produced antigens have been delivered to FBS and Scripps Research for preclinical evaluation in support of a potential non-mRNA vaccine candidate targeting Bundibugyo ebolavirus. The speed of this work is particularly important given the seve
- INSIDERLarge owner Francisco Trust Under Agreement Dated February 28, 1996 sold $124,958 worth of shares (95,392 units at $1.31), decreasing direct ownership by 3% to 3,280,272 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- SECDyadic International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- PRDyadic Announces Continued Listing on the Nasdaq Capital MarketJUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced that Nasdaq has confirmed that the Company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b). The Company’s common stock continues to be listed and traded on The Nasdaq Capital Market. "We are pleased that the Nasdaq continued listing matter has been resolved and that Dyadic’s common stock will continue to be listed on Nasdaq," said Mark Emalf
- PRDyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme ProgramJUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food, nutrition, bio-industrial and biopharmaceutical markets, today announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing. The program builds on the successful commercialization of EN3ZYME™, Dyadic's first proprietary bio-industrial enzyme product developed in collaboration with Fermbox Bio and further demonstrates the repeatable product development capabili
- PRGlobal Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial PotentialJUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today highlighted continued progress across multiple global health collaborations that further validate the capabilities of its proprietary C1 protein production platform while supporting its broader commercialization strategy. Dyadic’s C1 platform is designed to enable rapid, high-yield, and cost efficient production of recomb
- INSIDERLarge owner Francisco Trust Under Agreement Dated February 28, 1996 sold $343,763 worth of shares (172,864 units at $1.99), decreasing direct ownership by 5% to 3,375,664 units (SEC Form 4)4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
- PRDyadic Expands IP Protection and Business Development Activities in JapanJUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology. The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyces heterothallica recombinant protein expression technology. This
- SECDyadic International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form DEFA14A filed by Dyadic International Inc.DEFA14A - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECSEC Form 8-K filed by Dyadic International Inc.8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
- SECDyadic International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
DYAI FAQ
6 questionsWhat does Dyadic International Inc. do?
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen...Where does DYAI stock trade?
Dyadic International Inc. (DYAI) is listed on NASDAQ.What sector and industry is DYAI in?
Dyadic International Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about DYAI?
Dyadic International Inc. has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $300.00 price target on 2025-10-23. Recent price targets range from $300.00 to $700.00.What companies are similar to DYAI?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare DYAI side-by-side with any of them on Quantisnow.How can I track DYAI on Quantisnow?
Quantisnow aggregates Dyadic International Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DYAI to receive live email and push alerts on every new disclosure.